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Introduction
Klebsiella pneumoniae is one of the most common
gram negative bacteria encountered by the physicians
worldwide as a cause of infections in humans.1 It was
recognized initially as an etiological agent of pneumonia and
urinary tract infection; however its epidemiology in the
community had changed over the last 20 years with the
emergence of virulent capsular serotypes.2 Today K.
pneumoniae is associated with a wide spectrum of infections
including a distinctive invasive K. pneumoniae syndrome.3
Despite gaining popularity as an emerging pathogen in the
community the vast majority of K. pneumoniae infections are
nosocomial and it is reported to be amongst the 10 most
common nosocomial pathogens in various studies.1,4
This increased burden of K. pneumoniae infections is
compounded by increase in Extended Spectrum Beta
Lactamase (ESBL) producing isolates globally.5,6 ESBL are
plasmid mediated enzymes that are able to hydrolyze a wide
variety of penicillins and cephalosporins including third
generation cephalosporins and monobactams. However the
ESBL producing bacteria remain susceptible to cephamycins
and carbapenems. These enzymes have been reported more
frequently in E. coli and K. pneumoniae. Cross transmission
of these ESBL producing bacteria in hospitalized settings
have been implicated for nosocomial infections world wide.
Incidence of ESBL in K. pneumoniae differ geographically
and was reported as a part of MYSTIC study (1997-2003) to
be 12.3% for North America, 51.9% for South America,
16.7% for Northern Europe, 24.4% for Southern Europe,
58.7% for Eastern Europe and 28.2% for Asia Pacific
region.5 In addition emergence of carbapenem resistance due
to metallobatelactamse enzyme production in K.
pneumoniae is being reported worldwide.7 The main
concerns with ESBL are limited treatment options, resistance
to multiple classes of antimicrobials leading to multidrug
resistant ESBL phenotype (MDR ESBL), increased
mortality and cost of management.8
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Abstract
Objective: To report trends of extended spectrum beta lactamase (ESBL), multidrug resistant (MDR) ESBL and
emergence of carbapenem resistant ESBL producing isolates of K. pneumoniae from Pakistan. 
Methods: Retrospective analysis of laboratory data was conducted (2002-2007). K. pneumoniae were isolated
and identified from clinical samples using standard microbiological techniques. Antimicrobial susceptibility testing
was performed by Kirby Bauer. ESBL was detected using combined disc method. Statistical analysis was
performed using SPSS version 13.
Results: 15914 K. pneumoniae isolates (2002-2007) were analyzed. Significant increase in ESBL and MDR
ESBL producing K. pneumoniae (p=<0.0001) was observed. We found significant association of ESBL positive
K. pneumoniae with age less than 10 years, males and blood isolates (p=0.001). 0.4% (n=23) of ESBL positive
isolates were carbapenem resistant. 
Conclusions: Increase in ESBL and carbapenem resistant K. pneumoniae is a serious threat to public health requiring
continuous surveillance and use of appropriate screening tests for laboratory detection (JPMA 60:186; 2010).
In Pakistan ESBL production in K. pneumoniae has
been reported from different centers,9,10 however changing
trends of resistance in K. pneumoniae particularly ESBL
phenotype and MDR ESBL over period of time has not been
determined. Of more concern is the emergence of carbapenem
resistant isolates at our center. Carbapenem resistant K.
pneumoniae has not yet been reported from Pakistan; to the
best of our knowledge this is the first report, documenting
changing trends of ESBL producing K. pneumoniae isolates
and emergence of carbapenem resistance in these strains from
Karachi, Pakistan.
Materials and Methods
Setting: This descriptive study (January 2002 to 2007)
was conducted at The Aga Khan University Hospital
(AKUH), a 550 bedded tertiary care centre located in Karachi.
The hospital and its clinical laboratory are accredited with
Joint Commission of International Accreditation (JCIA). The
laboratory has been participating in external quality control
surveys with College of American Pathologists (CAP) since
1992. Clinical microbiology laboratory provides services to
inpatients and patients from other hospitals, clinics and in the
community. Moreover the clinical laboratory of AKUH has a
unique system of national network of collection centers
located in more than 50 major cities and towns of all four
provinces of Pakistan. This extensive networking makes our
laboratory data representative of strains prevalent across the
country.
Specimen Selection: All clinical samples yielding
growth of K. pneumoniae were selected. Data retrieved from
centralized database included: identification, age, sex and
location (inpatient or outpatient), year and month of isolation,
specimen type, city from which specimen was received and
susceptibility pattern. Duplicate specimens from same patients
were excluded. Methodology of identification, susceptibility
testing and quality control of the organism remained similar
throughout the study period. 
Microbiological Methods: All clinical samples were
processed and isolated according to the standard
microbiological methods.11 Isolates were identified
biochemically using conventional tests as per protocol.11
Isolates from blood and other sterile body sites were identified
using API 20E (Bio Merieux France). 
Antimicrobial susceptibility test:
Antimicrobial susceptibility testing was performed
by Kirby Bauer method as per Clinical Laboratory
Standards Institute (CLSI).12 Antimicrobial discs tested
were ampicillin (10µg), amoxicillin-clavulanic acid
(20/10µg), piperacillin-tazobactam (100/10µg), ceftriaxone
(30 µg), aztreonam (30 µg), gentamicin (10 µg), amikacin
(30 µg), ofloxacin (5 µg), trimethoprim-sulfamethoxazole
(1.25/23.75 µg), and imipenem (10 µg). ESBL production
was detected by combined disc method (ceftriaxone alone
and ceftriaxone-clavulanic acid) using the same standard.12
E.coli ATCC 25922 and K. pneumoniae ATCC 700603 were
used as the quality control strain. MDR ESBL were those
ESBL positive K. pneumoniae that were also resistant (co-
resistance) to aminoglycosides, fluoroquinolones and
cotrimoxazole.
Statistical Analysis:
Descriptive analysis was done by calculating
frequencies and percentages. Chi-square test was used with
appropriate correction for the observation. Fisher exact test
was applied to see the significance of difference between
the resistance levels of various drugs in ESBL producer
strains and non ESBL producer strains. All analysis was
done on SPSS version 16. P < 0.05 was considered
significant.
Results
15914 K.pneumoniae isolates were recovered during
the study period of 6 years (2002-2007). Details of these
isolates are mentioned in Table-1. 
Antimicrobial Resistance Pattern of Klebsiella
pneumoniae isolates: 
An increasing trend of resistance to all the antibiotics
tested was noted over years. Resistance to amikacin in 2002
was 9.9 % and gentamicin was 24.4% respectively, this
increased to 11.3% and 35.4% (p= <0.0001) in 2007
respectively. Similarly resistance to ciprofloxacin increased
from 14.8% in 2002 to 24.0% (p= <0.0001) in 2007.
Resistance to piperacillin/tazobactam increased from 3.8% in
2002 to 4.2% (p= <0.0001) in 2007. Screening for ESBL
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Figure: Year wise isolation rate of ESBL producing and MDR ESBL K.pneumonaie
(KP) showing significant increase (p value for trend 0.001).
phenotype was introduced in our laboratory in 2002 and an
increasing trend of ESBL isolation was noted from 2002-2007
(Figure). Similarly isolation of MDR ESBL followed the same
trend (p=<0.0001) (Figure). Isolates resistant to carbapenem
were first isolated in 2004. 0.4% (n=23) of ESBL positive
isolates detected through out study period were found resistant
to carbapenem. 47.8% (n=11) of carbapenem resistant ESBL
positive isolates were yielded from patients treated in
intensive care units.
Demographic details of ESBL phenotype of
Klebsiella pneumoniae:
Age <10 years as opposed to other age groups was
significantly associated with isolation of ESBL positive K.
pneumoniae (Table-1). Further stratification of this age group,
identified neonates as the most commonly affected. Similarly
males and isolates from blood were significantly associated
with ESBL phenotype (Table-1). 
Antimicrobial resistance pattern of ESBL
phenotypes of Klebsiella pneumoniae: 
Table-2 shows comparison of cross resistance of
ESBL positive and non-ESBL isolates of K. pneumoniae to
other antimicrobial agents. ESBL positive isolates of K.
pneumoniae had significantly higher resistance to other
groups of antibiotics. Similarly combined resistance to other
classes of antimicrobials (n=794) was significantly associated
with ESBL positive isolates (p=<0.0001).
Discussion
K. pneumoniae is an important pathogen responsible
for serious infections in both community and hospitalized
settings. Urinary tract was the most common site of infections
followed by bacteraemia in our study. Our findings are
consistent with other studies reporting K. pneumoniae to be
responsible for 6 to 17% of all hospital acquired urinary tract
infections and 4-15% of blood stream infections.1
Globally increasing resistance trends to multiple
antibiotics in K. pneumoniae have complicated the
management of these infections. We also noted an increased
resistance to the commonly used antibiotics against K.
pneumoniae infections. More concerning was the emergence
and increase in the isolation rates of ESBL producing K.
pneumoniae over the years. Studies from both developed and
developing countries have reported an increasing trend in the
isolation of ESBL positive K. pneumoniae.13-15 We found
significant increased isolation of ESBL positive K.
pneumoniae in age less than 10 years, males and blood
isolates. 
Interestingly when age as a risk factor was further
analyzed we observed that K. pneumoniae isolates from
neonates and children less than 1 years of age had significantly
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Table-1: Comparison of ESBL producing Klebsiella Pneumoniae within age groups, gender, specimen source
and patient status (n=15914) isolated at Aga Khan University Hospital 2002-07.
Characteristics Total KP strains ESBL producing KP (n) %† p values
Age in years* <10 3007 1312 44‡ <0.001 
11 to 20 960 271 28
21 to 40 3554 806 23
41 to 60 4007 1223 30.5
60+ 4350 1380 32
Gender** Male 7257 2893 40‡ <0.001 
Female 8632 2104 24
Specimen Source*** Blood 1752 1053 60‡ <0.001 
Urine 10938 2620 24
Wound 1152 476 41
Respiratory 1552 620 40
Sterile fluids 463 219 47
CVP 57 28 49
*Data from 36 patients missing, **Data from 25 patients missing, ***Data from 13 patients missing.
‡ Bold values reflect category that is significantly higher than the other categories.
† Values are rounded to the nearest number.
Table 2: Cross-resistance of ESBL producing and
non ESBL producing K. pneumoniae isolates (n=15914) to
other groups of antibiotics 2002-07.
Antibiotics ESBL negative ESBL producing p values
(n=10898) (%) (n=5016) (%)
Carbapenem 0 (0) 23 (0.4)* -
Ofloxacin 932 (8.5) 2644 (52.7) < 0.0001
Piperacillin/Tazobactam 0 (0) 368 (7) -
Gentamicin 1034 (9.5) 3969 (79) < 0.0001
Amikacin 231 (2) 1386 (28) < 0.0001
Co-trimoxazole 2489 (23) 4076 (81) < 0.0001
Combine antibiotic
resistance** 88 (0.8) 794 (15.8) < 0.0001
*Carbapene resistant isolates showed combined resistance to all other classes of
antibiotics tested.
**Isolates showing combine resistance to amikacin + gentamicin + fluoroquinolone
and contrimoxazole.
high isolation rate of ESBL production. Various studies have
reported increased isolation and increased rates of nosocomial
infections with ESBL producing K. pneumoniae in their
neonatal and paediatric patients both from developed and
developing countries.16-18 Our institution has observed
intermittent out breaks of infections with ESBL producing
K.pneumoniae isolates in its neonatal intensive care unit and
paediatric wards over the study period and increased isolation
of ESBL positive isolates in our study could be related to this
fact. Whether these isolates are epidemiologically related and
whether ESBL K. pneumoniae has become endemic pathogen
in our hospital, remains to be studied. Age greater than 60
years has been reported as common risk factor for ESBL K.
pneumoniae infections, but we did not find this association
statistically significant in our study sample.19,20
Increased ESBL production was seen in males as
compared to females in our study. Male gender as a risk factor
for ESBL production has been reported in literature however
the reason for this association is not discussed in much
detail.21 We hypothesize that males in general have more
obstructive uropathies leading to frequent urinary
catheterization and have more chronic pulmonary and
cardiovascular diseases that in turn lead to increased
hospitalization and hence increase ESBL. 
Bacteraemic isolates in our study were more likely to
be associated with ESBL production as opposed to non
bacteraemic isolates. This finding was unusual as studies have
reported non bacteraemic isolates to be more frequently
associated with ESBL production.22,23 However globally
blood stream infections caused by ESBL producing strains of
enterobacteriaceae is on the increase that has serious
implications on mortality rates and overall cost of
management of these infections especially in developing
countries like Pakistan.21
ESBL positive strains of K. pneumoniae were found to
be significantly more resistant to aminoglycosides, quinolone
and cotrimoxazole as opposed to ESBL negative strains as
reported previously.1,8,24 The prevalence of these multidrug
resistant ESBL (MDR ESBL) strains of K. pneumoniae is also
reported to be on the rise.25 K. pneumoniae as an infecting
organism has been identified as an independent risk factor for
these MDR ESBL strains.25This multidrug resistance is due to
simultaneous transmission of ESBL gene with plasmids that
encode resistance to aminoglycosides, quinolones and
trimethoprim sulfmethoxazole.8
Owing to increased prevalence of the MDR ESBL
internationally reliance on carbapenem has led to emergence
of carbapenem resistance.10One of the alarming finding of our
study was the emergence of extensively resistant ESBL
producing K. pneumoniae isolates resistant to all other
antibiotics effective for treatment including carbapenem,
ciprofloxacin, aminoglycosides and piperacillin-tazobactam.
These isolates were sensitive only to colistin and polymixin.
Susceptibility of these extensive resistant isolates with
tigecycline, a newer glycylcycline, now recommended as
option for the management of infections with carbapenem
resistant strains needs to be evaluated in our setup.10 Extensive
resistant strains of K. pneumoniae started to emerge in year
2004 in our hospital, although not statistically significant in
the current study, an overall increase in their isolation rate is
noted in recent years. This poses a great challenge to our
clinicians owing to their difficult and complicated
management.
Our study data have certain limitations. Firstly the
data presented here were not collected in a programmed
survey of drug resistance but obtained as part of routine
analysis of specimens submitted to the laboratory therefore
is subjected to sampling bias. Secondly due to non
availability of the history we were not able to differentiate
our strains to community and nosocomial strains. Thirdly
treatment history of the patient was not available therefore
we were not able to associate resistance with antibiotics
used. Nevertheless, despite these limitations this is the first
study from Pakistan reporting ESBL trends over years on a
large number of K. pneumoniae isolates. We are also first to
report the emergence of carbapenem resistance in K.
pneumoniae isolates from Pakistan.
Conclusion
Increasing prevalence of ESBL producing isolates of
K.pneumoniae and emergence of extensively resistant isolates
with resistance to all second line antibiotics is a call for concern
and mandates strict adherence to antibiotic selection and
restriction policies in community and hospitals in Pakistan. 
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